Treatment of urinary tract infections – of recommendations for clinical practice
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The paper presents the examination and treatment of 58 women, average age 46,3 years, with recurrent uncomplicated urinary tract infections (UTI). A modern approach to the treatment of patients with UTI and prevent recurrence of infection, which should be based on the use of not only antibacterial but imunoaktyvnyh drugs. That purpose Tseforala Soljutab (400 mg/day) for 3-7 days while eating Uro-blacking (6 mg / day) for 3 months, which is an effective and safe method of eradication of the pathogen and prevent a recurrence of UTI. The study relapse rate decreased from 4,4 ± 1,1 episodes in 6-month period prior to oral immunotherapy, to 1,7 ± 1,4 episode 9-month monitoring phase. These parameters correspond to reduce the frequency of relapses in an average of 65.6 %%.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Betsy Foxman, PhD, 2002. Epidemiology of Urinary Tract Infections: Incidence, Morbidity and Economic Costs.
Anne K. Ellis, MD, and Sarita Verma, 2000. Quality of Life in Women With Urinary Tract Infections: Is Benign Disease a Misnomer?
Mangiarotti P., Pizzini С., Fanos V., 2000. Antibiotic Prothylaxis with Relapsing Urinary Tract Infections: Review.
Kalpana Gupta, MD, MPH; Delia Sholes, PhD; Walter E. Stamm, MD,1999. Increasing Prevalence of Antimicrobial Resistance Among Uropathogens CausingAcute Uncomplicated Cystitis in Women.
Hartwing Wilhelm Bauer et al., 2002. Prevention of recurrent urinary tract infections with immuno-active E.coli fractions: a meta-analysis of five placebo-controlled double-blind studies.
Silvia Schmidhammer et al., 2002. An Escherichia coli – Based oral vaccine against urinary tract infections potently activates human dendritic cells.
Wiltrud Baier et al., 1997. Studies on the Immunogenicity of an Escherichia coli Extract after Oral Application in Mice.
Иммуностимуляция бактериальными компонентами: II. Исследование эффективности и мета-анализ бактериального экстракта ОМ-89, 2002.
Оральная иммунотерапия рецидивирующих инфекций мочевыводящих путей: двойное слепое плацебо-контролируемое многоцентровое исследование, 2002.
Уро-Ваксом и лечение рецидивирующих инфекций мочевыводящих путей у взрослых: рандомизированное многоцентровое двойное слепое клиническое испытание, 2002.
Popa G. et al.,2000. Recurrent post-menopausal urinary tract infections.
Профилактика рецидивирующих инфекций мочевыводящих путей у девочек. Иммунотерапия препаратом ОМ-89 в сравнении с профилактическим приемом нитрофурантоина в рандомизированном пилотном исследовании, 2002.
Bottex C. et al.,1989. Efficacy of an Immunomodulator in Compensating Antibiotic-Induced Immunosupression.
Walter E. Stamm and S. Ragnar Norrby, 2001. Urinary Tract Infections: Disease Panorama and Challenges.
William E/ Hauser, Jr. and Jack S. Remington, 1984. Effect of Antimicrobial Agents on the Immune Response.
